Cargando…

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective

Nanotechnology is an important application in modern cancer therapy. In comparison with conventional drug formulations, nanoparticles ensure better penetration into the tumor mass by exploiting the enhanced permeability and retention effect, longer blood circulation times by a reduced renal excretio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Eleonora, Spallarossa, Andrea, Tasso, Bruno, Villa, Carla, Brullo, Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235113/ https://www.ncbi.nlm.nih.gov/pubmed/34207175 http://dx.doi.org/10.3390/ijms22126538

Ejemplares similares

Nanotechnology for Pediatric Retinoblastoma Therapy
por: Russo, Eleonora, et al.
Publicado: (2022)

Indole Antitumor Agents in Nanotechnology Formulations: An Overview
por: Russo, Eleonora, et al.
Publicado: (2023)

Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
por: Brullo, Chiara, et al.
Publicado: (2021)

The Development of FAK Inhibitors: A Five-Year Update
por: Spallarossa, Andrea, et al.
Publicado: (2022)

The Development of BTK Inhibitors: A Five-Year Update
por: Tasso, Bruno, et al.
Publicado: (2021)

Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
por: Zhou, Xiaohan, et al.
Publicado: (2020)

Amino-Pyrazoles in Medicinal Chemistry: A Review
por: Lusardi, Matteo, et al.
Publicado: (2023)

Microbiological Screening of 5-Functionalized Pyrazoles for the Future Development of Optimized Pyrazole-Based Delivery Systems
por: Brullo, Chiara, et al.
Publicado: (2022)

Hydrogel Formulations of Antibacterial Pyrazoles Using a Synthesized Polystyrene-Based Cationic Resin as a Gelling Agent
por: Alfei, Silvana, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Mono- and di-acylated imidazolidine-2-thione derivatives: synthesis, cytotoxicity evaluation and computational studies
por: Scarsi, Anna, et al.
Publicado: (2022)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
por: Dervisis, Nikolaos, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
por: Lin, Nancy U, et al.
Publicado: (2004)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective
por: Eckstein, Niels, et al.
Publicado: (2014)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Cancer nanotechnology: current status and perspectives
por: Kemp, Jessica A., et al.
Publicado: (2021)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
por: Xu, Wenjing, et al.
Publicado: (2022)

Targeting USP-7 by a Novel Fluorinated 5-Pyrazolyl-Urea Derivative
por: Morretta, Elva, et al.
Publicado: (2023)

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
por: Petrazzuolo, Adriana, et al.
Publicado: (2022)

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
por: Hojjat-Farsangi, Mohammad
Publicado: (2014)

Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy
por: Jampilek, Josef, et al.
Publicado: (2022)

Receptor Tyrosine Kinase-Targeted Cancer Therapy
por: Yamaoka, Toshimitsu, et al.
Publicado: (2018)

Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy
por: Aloisio, Annamaria, et al.
Publicado: (2021)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

DNA Nanotechnology for Cancer Therapy
por: Kumar, Vinit, et al.
Publicado: (2016)

Nanotechnologies in Pancreatic Cancer Therapy
por: Manzur, Ayesha, et al.
Publicado: (2017)

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
por: Poliaková, Michaela, et al.
Publicado: (2018)

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
por: Shyam Sunder, Sunitha, et al.
Publicado: (2023)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_55vp0srbcjiapra6o156tcirgl